期刊文献+

NSCLC患者血浆游离DNA检测的临床意义 被引量:3

Clinical significance of plasma cell free DNA detectionin in non-small cell lung cancer patients
下载PDF
导出
摘要 目的 评估血浆游离DNA含量在非小细胞肺癌(non-small cell lung cancer,NSCLC)诊疗中的应用价值。方法 收集61例非小细胞肺癌患者和18例健康人的血浆,提取血浆游离DNA,荧光定量PCR方法 检测DNA浓度。结果 健康人血浆游离DNA水平中位数为73.70(53.49~85.03)ng/ml,非小细胞肺癌患者血浆游离DNA水平为179.43(160.94~401.34)ng/ml,两者间差异有统计学意义(P〈0.01)。血浆游离DNA含量与非小细胞肺癌患者的性别、年龄、吸烟状况及病理类型均无明显相关性,与有无转移存在相关性(P〈0.01)。结论 非小细胞肺癌患者的血浆游离DNA是一种潜在有价值的生物学标志物,可作为临床上诊断肺癌、预测疾病进展、快速评估治疗疗效的工具。 Objective To evaluate the dection of plasma cell free DNA content in the diagnosis and treatment of non-small cell lung cancer (NSCLC). Methods The plasma samples were collected from 61 cases of NSCLC patients and 18 healthy subjects. The plasma cell free DNA was extracted using GIAGEN reagent. The concentration of cell free DNA was detected by fluorescence quantitative PCR method. Results The level of plasma cell free DNA was 73.70 ( 53.49 - 85.03 ) ng/ml in control group and 179.43 ( 160. 94 - 401.34 ) ng/ml in NSCLC group ( P 〈 0. 01 ). Plasma cell free DNA was not correlated with gender, age, smoking and pathological type of NSCLC patients, but correlated with cancer metastasis ( P 〈 0. 01 ). Conclusion The dection of plasma cell free DNA can be used as a biological marker for diagnose and prognosis for NSCLC patients.
作者 王凯玲 任涛
出处 《同济大学学报(医学版)》 CAS 2016年第4期46-50,共5页 Journal of Tongji University(Medical Science)
基金 国家自然科学基金(81372347)
关键词 非小细胞肺肿瘤 游离DNA 液体活检 non-small cell lung cancer cell free DNA
  • 引文网络
  • 相关文献

参考文献17

  • 1田德增,梁永杰.肺癌的早期诊断进展[J].同济大学学报(医学版),2004,25(3):251-253. 被引量:4
  • 2Vasioukhin V, Anker P, Maurice P, et al. Point mutation of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia[ J ]. Br J Haematol, 1994,86 (4) : 774 - 779.
  • 3Sorenson GD, Pribish DM, Valone FH, et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood [ J ]. Cancer Epidemiol Biomarkers Prev, 1994,3 : 67 - 71.
  • 4Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature [ J ]. Clin Chim Acta, 2010, 411(21 -22) : 1611 - 1624.
  • 5Shapiro B, Chakrabarty M, Clhn EM, et al. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease [ J]. Cancer, 1983,51 ( 11 ) ,2116 - 2120.
  • 6. Szpechcinski A, Chorostowska-Wynimko J, Struniawski R, et al. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease[J]. Br J Cancer, 2015,113(3) : 476-483.
  • 7Ludovini V, Pistola L, Gregorc V, et al. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology [J]. J Thorac Oncol, 2008,3(4) : 365 -373.
  • 8Sozzi G, Conte D, Mariani L, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients [ J ]. Cancer Res, 2001,61 (12) : 4675 -4678.
  • 9Jylhivi J, Kotipelto T, Raitala A, et al. Aging is associated with quantitative and qualitative changes in circulating cell-free DNA: the Vitality 90 + study [ J ]. Mech Ageing Dev, 2011,132(1 -2) : 20-26.
  • 10Sozzi G, Conte D,Leon M, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer [J]. J Clin Oncol, 2003,21 (21) : 3902 - 3908.

二级参考文献26

  • 1邓水秋,余宗阳.血循环游离DNA在恶性肿瘤临床应用现状[J].华西医学,2009,24(12):3271-3273. 被引量:1
  • 2施春雷,韩宝惠.ASCO不可手术切除的非小细胞肺癌治疗指南——2003新版推荐指南[J].循证医学,2004,4(2):115-124. 被引量:114
  • 3Zhou J,Mulshine JL,Unsworth EJ et al.Purification and characterization of a protein that permits early detection of lung cancer.Identification of heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4[J].J Biol Chem,199
  • 4Fielding P,Turnbull L,Prime W,et al.Heterogeneous nuclear ribonucleoprotein A2/B-1 up-regulation in bronchial lavage specimens:a clinical marker of early lung cancer detec -tion[J].Clin Cancer Res,1999,5(12):4048-4052.
  • 5Piyathilake CJ,Frost AR,Manne U,et al.Nuclear accumulation of p53 is a potential marker for the development of squamous cell lung cancer in smokers[J].Chest,2003,123(1):181-186.
  • 6Martin B,Verdebout JM,Mascaux C,et al.Expression of p53 in preneoplastic and early neoplastic bronchial lesions[J].Oncol Rep,2002,9(2):223-229.
  • 7Liu Y,An Q,Li L,Zhang D,et al.Hypermethy-lation of p16INK4a in Chinese lung cancer patients:biological and clinical implications[J].Carcinogenesis,2003,24(12):1897-1901.
  • 8Kaneko M,Kusumoto M,Kobayashi T,et al.Computed tomography screening for lung carcinoma in Japan[J].Cancer,2000,89(11 Suppl):2485-2488.
  • 9Sobue T,Moriyama N,Kaneko M,et al.Screening for lung cancer with low-dose helical computed tomography:anti-lung cancer associa- tion project[J].J Clin Oncol,2002,20(4):911-920.
  • 10Qiao YL,Taylor PR,Yao SX,et al.Risk factors and early detection of lung cancer in a cohort of Chinese tin miners[J].Ann Epidemiol,1997,7(8):533-541.

共引文献10

同被引文献57

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部